Resources

Your selections:

Clear all

Show Filters

We found 278 resources that match your search.

Financial Disclosure Form for HPTN, Sep 2019

Clinical investigators disclosure of financial interests and arrangements.

Document Date:

Financial Disclosure Form for HVTN

HVTN IND study financial disclosure form.

Document Date:

Financial Disclosure Form for HVTN

Document Date:

Financial Disclosure Form for IMPAACT

Disclosure of financial Interests and arrangements form for IMPAACT Clinical Investigators.

Document Date:

Financial Disclosure Form for IMPAACT

Document Date:

Financial Disclosure Form for MTN

MTN financial disclosure/certification form.

Document Date:

Financial Disclosure Form for Non-networks

Non-network financial disclosure/certification form.

Document Date:

Financial Disclosure Forms for ACTG

AIDS clinical trials group network IND study financial disclosure form. .zip file includes ACTG Network IND Study Financial Disclosure Form (PDF) ACTG Network IND Study Financial Disclosure Form Template (PDF) ACTG Network IND Study Financial Disclosure Form Fillable (PDF)  

Document Date:

Fluconazole (Diflucan) Package Insert

DIFLUCAN (fluconazole), the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, as a powder for oral suspension.

GLA-SE

Document Date:

Glecaprevir and Pibrentasvir

Document Date:

GSK1265744 (Cabotegravir)

Document Date:

Guidance for DAIDS Electronic Trial Master Files

Document Date:

Guidelines for Electronic Submissions Via Email-EPR Guidelines

Guidelines for Electronic Submissions Via Email-EPR Guidelines

Document Date:

HEC Placebo Gel

Hepatitis B Vaccine Recombinant (Engerix-B)

Document Date:

Hepatitis B Vaccine Recombinant, Adjuvanted (Heplisav-B)

Document Date:

Hepatitis B Vaccine Recombinant, Adjuvanted (Heplisav-B)

Document Date:

High Level Summary of Changes for the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0

The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0 contains a number of changes detailed below when compared with the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 – December 2004 (…

Document Date:

HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL)

Document Date:

HIV-1 Vaccines AdC6-HIVgp140, AdC7-HIVgp140, CH505TF/GLA-SE

Document Date:

HPTN - Expedited Reporting to DAIDS and DAERS Refresher

.zip files contains Presentation to HPTN/IMPAACT Annual Meeting on Expedited Reporting to DAIDS and DAERS refresher course Expedited reporting via DAERS - Case Study

Document Date:

HVTN - Expedited Reporting to DAIDS and DAERS Refresher

.zip file contains: Presentation to HVTN Annual Meeting on Expedited Reporting to DAIDS and DAERS refresher course; Expedited reporting via DAERS - Case Study

Document Date:

Hydroxychloroquine Sulfate Package Insert

Document Date:

IBC RAC Guidance

Guidance and requirements for daids-supported research involving recombinant DNA.

Document Date: